Pancreatic cancer drug trial halted over safety signals
NCT ID NCT05525286
Summary
This early-phase trial tested an experimental drug called SOT102 for people with advanced pancreatic cancer. Researchers wanted to see if SOT102 was safe and effective when given alone or alongside standard chemotherapy. The study was stopped early because concerning side effects appeared at multiple dose levels, preventing researchers from finding a safe dose to continue testing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Main Campus
Cleveland, Ohio, 44195, United States
-
Hospital Universitario HM Sanchinarro
Madrid, Spain
-
Institut Gustave Roussy
Paris, France
-
Institut Jules Bordet
Brussels, Belgium
-
Masarykův Onkologický Ústav
Brno, Czechia
-
Universitair Ziekenhuis Leuven - Campus Gasthuisberg
Leuven, Belgium
-
VHIO - Vall d'Hebron Institut d'Oncologia
Barcelona, Spain
-
Washington University School of Medicine in St. Louis
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.